Integrin αD Activators

Mangiferin interacts with the PI3K/AKT pathway, which plays a critical role in integrin-mediated cell adhesion, thereby affecting the activation of Integrin αD. Similarly, Genistein, a tyrosine kinase inhibitor, can modulate the integrin signaling cascade essential for the activation of Integrin αD. Cilengitide and Cyclo(RGDyK) are compounds that impact integrin function by binding to the extracellular domain of integrins, which might lead to conformational changes and thereby influence Integrin αD activation. The inhibitory effects of Echistatin on other integrins suggest that Integrin αD activity could also be altered through integrin network interactions.

EDTA, as a chelating agent, removes divalent cations from the cellular environment, which are necessary for the proper conformation and activation of integrins, thus indirectly affecting the activation state of Integrin αD. Peptides such as Fibronectin Inhibitor and AP5 can competitively inhibit integrin-ligand interactions, altering the functional state of Integrin αD. Tirofiban and SB273005, both integrin antagonists, may modify the integrin signaling landscape, potentially influencing the activation of Integrin αD. NSC23766 targets Rac1, a molecule involved in integrin-mediated cell adhesion, which could lead to changes in the activation of Integrin αD due to alterations in downstream signaling. Lovastatin affects the biophysical properties of the cell membrane by altering cholesterol levels, which can influence the localization and signaling of integrins, including Integrin αD.